Cascador Health

This year, Laurent Laffineur (Head of Strategic Partnerships) of Cascador Health will be at ISPOR Europe 2024 in Barcelona from November 18-20! Cascador Health is especially focused on exploring how Real-World Data (RWD) can drive meaningful advancements in clinical trials, market access, and therapy adoption—key areas where Cascador Health is dedicated to making an impact. If you’re attending ISPOR, let’s connect to share insights and explore how we can collaborate to create smarter, data-driven solutions. Feel free to reach out—I’d love to connect! 🌍🤝 #ISPOREurope2024 #CascadorHealth #RWD #ClinicalTrials #MarketAccess #TherapyAdoption #Barcelona

We're excited to share the news of the online publication of our article "Real-world effectiveness of dupilumab in a European cohort of CRSwNP" in the Journal of Allergy and Clinical Immunology (JACI). Thanks to CHRINOSOR Principal Investigator Prof Dr Claus Bachert, to the first coauthors Prof Dr Sven Schneider, Dr Sven Seys, and Joost de Kinderen, to all other coauthors, and the CHRINOSOR consortium for their collaboration on this important milestone. Stay tuned for more CHRINOSOR news to come. Find the article via https://lnkd.in/eb6XviGx Find more news via https://cascador.health/ #CHRINOSOR #RWE #RWD #dupilumab #CRSwNP #biologics #immunology #JACI Universitätsklinikum AKH Wien Amsterdam UMC LKH-Univ. Klinikum Graz Universitätsklinikum Düsseldorf CHU de Lille Policlinico Umberto I

WODC 2024….that’s a wrap! When it comes to leveraging Real-World Data (RWD), the needs for rare diseases aren’t all that different from those of more common diseases. Across the board, we seek the same foundational outcomes: ✅ Better Patient Insights: Regardless of disease prevalence, the goal is to understand the patient’s journey, improve outcomes, and personalize care. ✅ Improved Decision-Making: Whether treating a rare genetic disorder or managing diabetes, RWD is critical for informed clinical and regulatory decisions. ✅ Value Demonstration: Payers, providers, and patients all require evidence of treatment effectiveness, and RWD serves as a vital tool in demonstrating this. Yes, challenges in rare disease research, such as smaller patient populations and fragmented data, can be more pronounced. But by aligning our RWD strategies across diseases, we can accelerate progress, improve healthcare delivery, and drive innovation for all patients. Let’s focus on collaboration and advancing RWD capabilities across the entire healthcare spectrum! #RealWorldData #RareDiseases #HealthcareInnovation #DataDrivenCare #PrecisionMedicine

Interesting session this morning on the last day of the World Orphan Drug Congress Europe on "The use of RWD in orphan drug development and access pathways". Some quotes: "Registries in Rare Diseases are critical a lot of data is not captured in EHR's" "Regulators love to see RCTs, which are often not ethical and unfeasible in rare diseases" "Include patients in study designs as they know the primary outcomes that matter" "Critically important when collecting data is data quality; also, the possibility of linking data from multiple sources and the ability to link clinical outcomes with PROMS/PREMS is super interesting" With regards to registries and linking data, Cascador Health is a party to talk to. Reach out to learn more about how we can help! #rwd #rarediseases #registries

Day 2 - The JCA (Joint Clinical Assessment) will be introduced on a rolling basis for products requesting European Medicines Agency (EMA) regulatory approval, starting with cancer medicines and ATMPs (including oncologic orphan drugs and ATMPs for orphan diseases) in 2025. How will RWD be relevant? This slide summarizes it pretty well. Sources of RWD: Electronic Health Records (EHR), medical claims, billing data, administrative healthcare databases, and patient-generated data are all sources of RWD. Purpose (examples): - Pre-trial: 1. Identify patient baseline characteristics, prognostic, and predictive factors. 2. Support the strategy for recruiting patients, especially in rare diseases. 3. Define pragmatic trials based on real-world conditions. - Support HTA dossier: 1. Assess the use of a health technology in real-world settings. 2. Assess the effectiveness and/or safety of health technologies. 3. Conduct indirect comparisons between treatments (where randomized controlled trials may not provide direct comparisons). Consideration in JCA: - Will be considered: RWD is important for assessment and will definitely be factored into the decision-making process. - Certainty of results, data validity, exclusion of biases: HTA will focus on whether the data provides reliable, valid results with minimal bias. - Supporting RCT (Randomized Controlled Trials): RWD can be used to complement or support the results of traditional RCTs. - Important and critical for responding to selected PICO: RWD is essential for addressing the key questions of PICO (Population, Intervention, Comparison, Outcome) in assessments.

Fantastic presentations yesterday, exploring the role of RWD/RWE in rare disease treatment. Key highlights include: - RWD in Early Access Programs: Different countries (USA, France, Germany) have varying regulations on RWD submission for investigational therapies, emphasizing the need for global alignment. - RWE & Affordability: RWE is driving value-based pricing agreements, shaping commercial strategies, and aiding R&D in real-world settings. - RWE in HTA Decisions: Real-world data is increasingly used in health technology assessments (HTAs) for innovative therapies, though its influence varies by country. - Global RWD Support: Regulators in the UK, EU, USA, and France are backing RWD to improve clinical studies and post-market surveillance, especially with initiatives like FDA’s RWE Program and DARWIN EU. -Pharma RWD Usage: RWD is critical across drug development, from pre-clinical to post-launch, influencing trial design, pricing, and safety. Connect at the Cascador Health booth to talk more about these evolutions! #RWE #RWD #RareDiseases #Pharma #HealthcareInnovation

Day 1 of the World Orphan Drug Congress Europe. Looking forward to great sessions and meetings at our booth! Cascador Health #realworlddata #rwd

On my way to World Orphan Drug Congress Europe in Barcelona. Drop by our booth to talk about the RWD solutions that Cascador Health brings!

Cascador Health is excited to announce our participation in the upcoming World Orphan Drug Congress Europe from 23 to 25 October! Visit booth 64 to discover more about Cascador Health and our solutions as an RWD integrator. Click here for more info: https://lnkd.in/esU7EFd #WorldOrphanDrugCongress #HealthcareSolutions #RWDintegrator

Cascador Health will be present in Freiburg at Markets and Markets conference on 14 and 15 October. Come and visit us at the booth if you’re there. If not, do reach out to schedule a meeting to learn more on how we can help with your RWD needs for market access…and more!